Cytokinetics said on Tuesday its experimental heart disease drug significantly improved patients' ability to exercise compared to standard-of-care treatment in a late-stage study, sending shares of ...

Cytokinetics' PDUFA date for aficamten was extended to December 26th of 2025, due to the FDA's need to review a submitted ...

Cytokinetics (CYTK) announced that additional data arising from two analyses from SEQUOIA-HCM, the pivotal Phase 3 clinical trial of aficamten in ...

Cytokinetics, Incorporated SOUTH SAN FRANCISCO, Calif., May 16, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on May 15, 2025 it granted stock options to ...

The FDA extended aficamten's review by three months for REMS safety program finalization, causing Cytokinetics' stock to drop over 11%. The REMS requirement is expected and does not indicate ...

Cytokinetics has shared positive top-line results from a late-stage study of its investigational oral cardiac myosin ...

On Wednesday, 21 May 2025, Cytokinetics (NASDAQ:CYTK) participated in the RBC Capital Markets Global Healthcare Conference 2025, providing a comprehensive update on its drug development pipeline.

SOUTH SAN FRANCISCO, Calif. (AP) — Cytokinetics Inc. (CYTK) on Tuesday reported a loss of $161.4 million in its first quarter. On a per-share ...

The stock options and RSUs were granted as material inducements to employment in accordance with Nasdaq Listing Rule 5635 (c) ...